The intersection of metabolic medicine and oncology reveals an unexpected ally in fighting one of gynecology's deadliest cancers. While ovarian cancer's late-stage diagnosis and treatment resistance have long frustrated clinicians, emerging evidence suggests that metformin—the world's most prescribed diabetes medication—may offer new therapeutic pathways for patients facing limited options.
The antidiabetic drug demonstrates dual-action anticancer mechanisms that extend beyond simple glucose control. Metformin activates the AMPK pathway, directly disrupting cancer cell energy metabolism and survival signals. This metabolic interference appears particularly relevant for ovarian tumors, which often exhibit altered glucose utilization patterns. Additionally, the drug modulates the tumor microenvironment by reprogramming immune cell populations, including macrophages and T cells, potentially overcoming the immunosuppressive conditions that typically shield ovarian cancers from therapeutic intervention.
This metabolic approach represents a significant departure from conventional ovarian cancer treatment paradigms, which rely heavily on surgery combined with platinum-based chemotherapy and PARP inhibitors. The appeal of metformin lies not only in its established safety profile from decades of diabetes management but also in its potential to address treatment resistance—a hallmark of advanced ovarian disease. However, translating promising preclinical findings into clinical benefit remains challenging. The optimal dosing, patient selection criteria, and combination strategies with existing therapies require careful investigation. While metformin's dual role as metabolic modulator and immune system activator offers theoretical advantages, rigorous clinical validation will determine whether this repurposed drug can meaningfully extend survival outcomes for ovarian cancer patients.